Technology
Health
Biotechnology

Microbot Medical

$7.90
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.04 (0.51%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell MBOT and other stocks, options, ETFs, and crypto commission-free!

About

Microbot Medical Inc. Common Stock, also called Microbot Medical, is a pre-clinical medical device company, which engages in the research, design, development, and commercialization of micro-robotics assisted medical technologies. Read More The company carries out its operations through the ViRob and TipCat platforms. The ViRob platform technology is an autonomous crawling micro-robot that can be controlled remotely or within the body. It makes use of the Self-Cleaning Shunt, a robotic system designed as the ventricular catheter portion of a Cerebrospinal Fluid shunt system, and is mainly used for the treatment of hydrocephalus and Normal Pressure Hydrocephalus. The TipCat platform, a self-propelling, flexible, and semi-disposable endoscope provides see-and-treat capabilities within tubular lumens in the human body such as the colon, blood vessels, and the urinary tract. The company was founded by Harel Gadot, Moshe Shoham, and Yosseph Bornstein on August 2, 1988 and is headquartered in Hingham, MA.

Employees
8
Headquarters
Hingham, Massachusetts
Founded
1988
Market Cap
23.39M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
650.92K
High Today
$7.98
Low Today
$7.72
Open Price
$7.87
Volume
16.49K
52 Week High
$19.40
52 Week Low
$0.5204

Collections

Technology
Health
Biotechnology
Medical
US
North America

News

Associated PressMar 1

Microbot Medical Maintains 2019 Milestone Targets Following Recent Court Decision

HINGHAM, Mass., March 01, 2019 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq CM: MBOT) is maintaining its milestone targets for 2019 following the recently announced decision of the New York State Supreme Court to rescind the Stock Purchase Agreement (“SPA”) Microbot entered into with two affiliated investors in connection with its June 2017 Registered Direct Offering of approximately $10 million of common stock. The rescission would require the investors to transfer back to Microbot the shares they pur...

1,263

Earnings

Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
—
Actual
—

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.